Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)

Background: Evaluation of the potential efficacy and safety of combination therapies for advanced soft tissue sarcomas (STS) has increased substantially after approval of trabectedin and pazopanib. Trabectedin’s introduction in Europe in 2007 depended mainly on its activity in so-called L-sarcomas (...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mar Drugs
Huvudupphovsmän: Kasper, Bernd, Reichardt, Peter, Pink, Daniel, Sommer, Michaela, Mathew, Monika, Rauch, Geraldine, Hohenberger, Peter
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4306943/
https://ncbi.nlm.nih.gov/pubmed/25591040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/md13010379
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk